Literature DB >> 11815435

Restoration of deficient membrane proteins in the cardiomyopathic hamster by in vivo cardiac gene transfer.

Yasuhiro Ikeda1, Yusu Gu, Yoshitaka Iwanaga, Masahiko Hoshijima, Sam S Oh, Frank J Giordano, Ju Chen, Vincenzo Nigro, Kirk L Peterson, Kenneth R Chien, John Ross.   

Abstract

BACKGROUND: One of the most important problems in developing in vivo cardiac gene transfer has been low transfection efficiency. A novel in vivo technique was developed, tested in normal hamsters, and the feasibility of restoring a deficient structural protein (delta-sarcoglycan) in the cardiomyopathic (CM) hamster evaluated. METHODS AND
RESULTS: Adenoviral (AdV) vectors encoding either the lacZ gene or delta-sarcoglycan gene were constructed. Hypothermia was achieved in hamsters by external body cooling to a rectal temperature of 18 to 25 degrees C. Through a small thoracotomy, the ascending aorta and the main pulmonary artery were occluded with snares, and cardioplegic solution containing histamine was injected into the aortic root; viral constructs were delivered 3 to 5 minutes later followed by release of the occluders and rewarming. Four days later, homogeneous beta-galactosidase expression was detected throughout the ventricles of the normal hearts (average 77.3+/-9.0% [SEM] of left ventricular myocytes). At 1 and 3 weeks after transfection, immunostaining showed extensive restoration of delta-sarcoglycan as well as alpha- and beta-sarcoglycan proteins to the myocyte membranes, despite loss of beta-galactosidase expression at 3 weeks. Also, at 3 weeks after gene transfer, there was significantly less progression of left ventricular dysfunction assessed as percent change in fractional shortening compared with controls.
CONCLUSIONS: This study demonstrates the feasibility of high efficiency in vivo myocardial gene transfer and shows application in improving the level of a deficient cardiac structural protein and cardiac function in CM hamsters. The approach should be useful for assessing effects of expressing other genes that influence the structure or function of the normal and failing heart.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11815435     DOI: 10.1161/hc0402.102953

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  23 in total

Review 1.  Mixed signals in heart failure: cancer rules.

Authors:  Masahiko Hoshijima; Kenneth R Chien
Journal:  J Clin Invest       Date:  2002-04       Impact factor: 14.808

Review 2.  Targeting calcium cycling proteins in heart failure through gene transfer.

Authors:  Federica del Monte; Roger J Hajjar
Journal:  J Physiol       Date:  2003-01-01       Impact factor: 5.182

Review 3.  The evolution of heart gene delivery vectors.

Authors:  Nalinda B Wasala; Jin-Hong Shin; Dongsheng Duan
Journal:  J Gene Med       Date:  2011-10       Impact factor: 4.565

4.  Delta-sarcoglycan gene therapy halts progression of cardiac dysfunction, improves respiratory failure, and prolongs life in myopathic hamsters.

Authors:  Masahiko Hoshijima; Takeharu Hayashi; Young E Jeon; Zhenxing Fu; Yusu Gu; Nancy D Dalton; Mark H Ellisman; Xiao Xiao; Frank L Powell; John Ross
Journal:  Circ Heart Fail       Date:  2010-10-29       Impact factor: 8.790

Review 5.  Progress in gene therapy of dystrophic heart disease.

Authors:  Y Lai; D Duan
Journal:  Gene Ther       Date:  2012-02-09       Impact factor: 5.250

6.  Disease rescue and increased lifespan in a model of cardiomyopathy and muscular dystrophy by combined AAV treatments.

Authors:  Carmen Vitiello; Stefania Faraso; Nicolina Cristina Sorrentino; Giovanni Di Salvo; Edoardo Nusco; Gerardo Nigro; Luisa Cutillo; Raffaele Calabrò; Alberto Auricchio; Vincenzo Nigro
Journal:  PLoS One       Date:  2009-03-31       Impact factor: 3.240

Review 7.  Cardiac gene therapy: optimization of gene delivery techniques in vivo.

Authors:  Michael G Katz; JaBaris D Swain; Jennifer D White; David Low; Hansell Stedman; Charles R Bridges
Journal:  Hum Gene Ther       Date:  2010-04       Impact factor: 5.695

Review 8.  Targeted gene therapy for the treatment of heart failure.

Authors:  Kleopatra Rapti; Antoine H Chaanine; Roger J Hajjar
Journal:  Can J Cardiol       Date:  2011 May-Jun       Impact factor: 5.223

9.  Multiphasic triacylglycerol dynamics in the intact heart during acute in vivo overexpression of CD36.

Authors:  Andrew N Carley; Jian Bi; Xuerong Wang; Natasha H Banke; Jason R B Dyck; J Michael O'Donnell; E Douglas Lewandowski
Journal:  J Lipid Res       Date:  2012-10-25       Impact factor: 5.922

Review 10.  Cardiac-targeted delivery of regulatory RNA molecules and genes for the treatment of heart failure.

Authors:  Wolfgang Poller; Roger Hajjar; Heinz-Peter Schultheiss; Henry Fechner
Journal:  Cardiovasc Res       Date:  2010-02-22       Impact factor: 10.787

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.